2m 2m 2m 2m 2m 2m 2m
OVID THERAPTCS (OVID)
NASDAQ
$2.41+$0.01 (+0.58%)
Price as of Jun 03, 2026 7:08 PM EDT- $509.5MMarket Cap
- 703.48%1-Year Change
- BiotechnologyIndustry
OVID THERAPTCS (OVID)
$2.41+$0.01 (+0.58%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 7.3M +1,181.27% | 566,000 -99.75% | 222.8M +0.13% | 222.5M +0.68% | |
Cost of Revenue | 0 N/A | 0 N/A | 0 N/A | N/A N/A | |
Gross Profit | 7.3M +1,181.27% | 566,000 -99.75% | 222.8M +0.13% | 222.5M +0.68% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -25.6M -30.42% | -36.8M +28.61% | -28.6M +16.12% | -24.6M -47.55% | |
Depreciation and Amortization Expense | 273,000 -55.46% | 613,000 +7.87% | 568,282 +10.88% | 512,505 +116.17% | |
Total Operating Expenses | 49.7M -20.43% | 62.5M +4.66% | 59.7M +4.60% | 57.1M -32.22% | |
Operating Profit | -42.4M -31.42% | -61.9M +4.39% | -59.3M +6.72% | -55.5M -144.72% | |
Interest Income | 2.0M -48.25% | 3.9M N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 2.0M -48.25% | 3.9M N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 25.0M -29.41% | 35.5M +410.65% | 6.9M +403.40% | 1.4M N/A | |
Income before Taxes | -17.4M -34.12% | -26.4M -49.50% | -52.3M -3.38% | -54.2M -143.63% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 -100.00% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -17.4M -34.12% | -26.4M -49.50% | -52.3M -3.38% | -54.2M -144.10% | |
Net Income from Continuing Operations Applicable to Common | -17.4M -34.12% | -26.4M -49.50% | -52.3M -3.38% | -54.2M -145.20% | |
Basic EPS and Net Income | -232.47 +62,729.73% | -0.37 -50.00% | -0.74 -3.90% | -0.77 -143.26% | |
Diluted EPS and Net Income | -232.47 +62,729.73% | -0.37 -50.00% | -0.74 -3.90% | -0.77 -143.75% | |
Basic Weighted Average Shares | 1,171 -100.00% | 70.9M +0.46% | 70.6M +0.22% | 70.4M +4.36% | |
Diluted Weighted Average Shares | 1,171 -100.00% | 70.9M +0.46% | 70.6M +0.22% | 70.4M +3.46% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 13.2M -49.99% | 26.3M -2.74% | 27.0M -39.73% | 44.9M -76.11% | |
Short-Term Investments | 56.5M +110.96% | 26.8M -66.02% | 78.8M -6.35% | 84.1M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 69.6M +31.20% | 53.1M -49.85% | 105.8M -17.96% | 129.0M -31.31% | |
Total Current Assets | 74.4M +32.94% | 55.9M -48.96% | 109.6M -16.58% | 131.4M -31.03% | |
Accumulated Depreciation | 1.6M +12.86% | 1.4M +40.57% | 1.0M +72.16% | 581,381 +121.73% | |
Property and Plant and Equipment and Net | 252,000 -41.80% | 433,000 -43.68% | 768,753 -33.03% | 1.1M +372.89% | |
Total Long-Term Assets | 0 -100.00% | 92,000 -56.10% | 209,574 -19.76% | 261,191 +59.17% | |
Total Assets | 150.9M +63.76% | 92.2M -36.01% | 144.0M -7.24% | 155.3M -20.19% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 8.3M -21.23% | 10.5M -8.30% | 11.5M +64.12% | 7.0M -52.75% | |
Total Long-Term Debt | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 12.0M -10.68% | 13.4M -9.06% | 14.8M -7.79% | 16.0M N/A | |
Total Liabilities | 20.3M -15.32% | 23.9M -57.42% | 56.2M +144.55% | 23.0M +55.38% | |
Retained Earnings | -321.7M +5.72% | -304.3M +9.51% | -277.9M +23.21% | -225.5M +31.61% | |
Total Stockholders Equity | 130.7M +91.51% | 68.2M -22.29% | 87.8M -33.62% | 132.3M -26.41% | |
Total Shares Outstanding | 130.2M +83.33% | 71.0M +0.45% | 70.7M +0.32% | 70.5M +0.14% | |
Cash Flow | |||||
Cash from Operating Activities | -38.3M -31.49% | -56.0M +22.23% | -45.8M -17.10% | -55.2M -146.56% | |
Capital Expenditures | 0 -100.00% | 71,000 +76.14% | 40,308 -96.71% | 1.2M +565.39% | |
Cash from Investing Activities | -49.9M -191.32% | 54.6M +2,215.55% | -2.6M -97.06% | -87.9M +4,725.04% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 75.2M +11,991.16% | 622,000 -97.96% | 30.5M +16,802.21% | 180,658 -80.02% | |
Financials Ratio | |||||
Gross Margin | 100.00% 0.00% | 100.00% 0.00% | 100.00% N/A | N/A N/A | |
Operating Margin | -585.20% -94.65% | -10,933.75% +40,992.72% | -26.61% +6.58% | -24.97% -144.42% | |
Return on Assets | -14.33% -35.99% | -22.38% -36.00% | -34.98% +12.93% | -30.97% -134.10% | |
Return on Equity | -17.51% -48.32% | -33.88% -28.77% | -47.57% +36.99% | -34.72% -131.57% | |
Revenue Growth | 1,181.27% +1,284.28% | -99.75% -74,095.55% | 0.13% -80.14% | 0.68% -99.96% | |
Current Ratio | 8.97 +68.78% | 5.32 -44.34% | 9.55 -49.17% | 18.79 +45.99% | |
Cash Ratio | 1.59 -36.51% | 2.50 +6.06% | 2.36 -63.28% | 6.42 -49.43% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow